---
layout: default
title: Vinorelbine
description: "Vinorelbine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 191
evidence_level: L3
indication_count: 10
---

# Vinorelbine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Vinorelbineï¼šå¾éå°ç´°èƒè‚ºç™Œåˆ° Ewing è‚‰ç˜¤

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Vinorelbine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Vinorelbine åŸæœ¬ç”¨æ–¼æ²»ç™‚éå°ç´°èƒè‚ºç™Œå’Œè½‰ç§»æ€§ä¹³ç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å° **Ewing è‚‰ç˜¤ (Ewing sarcoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **4 å€‹è‡¨åºŠè©¦é©—**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | Ewing sarcomaã€fibromatosis, gingivalã€fibroma of lungã€lung germ cell tumorã€pulmonary sulcus neoplasmã€hamartoma of lungã€small cell lung carcinomaã€lung cancerã€lung benign neoplasmã€lung hilum carcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.999% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 19 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. Ewing sarcoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">100.00%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Vinorelbine æ˜¯åŠåˆæˆçš„é•·æ˜¥èŠ±ç”Ÿç‰©é¹¼ï¼ˆVinca alkaloidï¼‰ï¼Œé€éé˜»æ–·å¾®ç®¡è›‹ç™½èšåˆæŠ‘åˆ¶æœ‰çµ²åˆ†è£‚ã€‚Ewing è‚‰ç˜¤æ˜¯ä¸€ç¨®é«˜åº¦å¢æ®–çš„æƒ¡æ€§è…«ç˜¤ï¼Œå°å¾®ç®¡æŠ‘åˆ¶åŠ‘å…·æœ‰æ•æ„Ÿæ€§ã€‚Vinorelbine åœ¨å¤šé …å…’ç«¥é›£æ²»æ€§è…«ç˜¤çš„è‡¨åºŠè©¦é©—ä¸­å±•ç¾æ´»æ€§ï¼ŒåŒ…æ‹¬ Ewing è‚‰ç˜¤ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT06451302](https://clinicaltrials.gov/study/NCT06451302) | N/A | ACTIVE_NOT_RECRUITING | 100 | è©•ä¼°ä¸­åœ‹å…’ç«¥ Ewing è‚‰ç˜¤é¢¨éšªåˆ†å±¤å°å‘æ²»ç™‚çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ |
| [NCT00003234](https://clinicaltrials.gov/study/NCT00003234) | Phase 2 | COMPLETED | 50 | ç ”ç©¶ Vinorelbine åœ¨å¾©ç™¼/é›£æ²»æ€§å…’ç«¥æƒ¡æ€§è…«ç˜¤ä¸­çš„æ•ˆæœï¼ŒåŒ…æ‹¬ Ewing è‚‰ç˜¤ |
| [NCT00180947](https://clinicaltrials.gov/study/NCT00180947) | Phase 2 | UNKNOWN | 210 | è©•ä¼° Vinorelbine èˆ‡ Cyclophosphamide çµ„åˆåœ¨é›£æ²»æ€§è…«ç˜¤ä¸­çš„æŠ—è…«ç˜¤æ´»æ€§ |
| [NCT05999994](https://clinicaltrials.gov/study/NCT05999994) | Phase 2 | RECRUITING | 105 | CAMPFIRE å…’ç«¥å’Œé’å°‘å¹´å‰µæ–°ç ”ç©¶ä¸»å”è­° |

### ç›¸é—œæ–‡ç»

ç›®å‰ç„¡å°ˆé–€é‡å° Vinorelbine ç”¨æ–¼ Ewing è‚‰ç˜¤çš„ PubMed æ–‡ç»æ”¶éŒ„ï¼Œä½†æœ‰ç›¸é—œçš„å…’ç§‘è…«ç˜¤ç ”ç©¶æ–‡ç»æ”¯æŒå…¶åœ¨é›£æ²»æ€§è‚‰ç˜¤ä¸­çš„æ‡‰ç”¨ã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. fibromatosis, gingival</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. fibroma of lung</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. lung germ cell tumor</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. pulmonary sulcus neoplasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hamartoma of lung</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. small cell lung carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. lung benign neoplasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. lung hilum carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. pulmonary blastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬022215è™Ÿ | æº«è«¾å¹³æ³¨å°„æ¶²10å…¬çµ²/å…¬æ’® | æ³¨å°„åŠ‘ | éå°ç´°èƒè‚ºç™Œï¼Œè½‰ç§»æ€§ä¹³ç™Œ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬024268è™Ÿ | æº«è«¾å¹³30æ¯«å…‹è»Ÿè† å›Š | è»Ÿè† å›ŠåŠ‘ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬024269è™Ÿ | æº«è«¾å¹³20æ¯«å…‹è»Ÿè† å›Š | è»Ÿè† å›ŠåŠ‘ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |
| è¡›éƒ¨è—¥è£½å­—ç¬¬060608è™Ÿ | å¨è‹¥è³“30æ¯«å…‹è»Ÿè† å›Š | è»Ÿè† å›ŠåŠ‘ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬025489è™Ÿ | ç¶­è«¾æ‹œæ³¨å°„æ¶² | æ³¨å°„åŠ‘ | éå°ç´°èƒè‚ºç™Œã€è½‰ç§»æ€§ä¹³ç™Œ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å‚³çµ±ç´°èƒæ¯’æ€§è—¥ç‰©ï¼ˆVinca alkaloidï¼‰ |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | é«˜åº¦ï¼ˆå—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ç‚ºåŠ‘é‡é™åˆ¶æ¯’æ€§ï¼‰ |
| è‡´åæ€§åˆ†ç´š | ä½åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è‚åŠŸèƒ½ã€ç¥ç¶“æ¯’æ€§è©•ä¼° |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œï¼›éœè„ˆæ³¨å°„éœ€æ³¨æ„å¤–æ»²é¢¨éšª |

## å®‰å…¨æ€§è€ƒé‡

### é‡å¤§è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆMajorï¼‰

| äº¤äº’ä½œç”¨è—¥ç‰© | æ©Ÿè½‰èªªæ˜ |
|-------------|---------|
| Clarithromycin | CYP3A4 æŠ‘åˆ¶åŠ‘ï¼Œå¢åŠ  vinorelbine è¡€ä¸­æ¿ƒåº¦å’Œæ¯’æ€§ |

### ä¸­åº¦è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆModerateï¼‰

| äº¤äº’ä½œç”¨è—¥ç‰© | æ©Ÿè½‰èªªæ˜ |
|-------------|---------|
| Aprepitant | CYP3A4 æŠ‘åˆ¶ |
| Dexamethasone | å¯èƒ½å½±éŸ¿ä»£è¬ |
| Simvastatin | CYP3A4 ç«¶çˆ­ |
| Rosuvastatin | è—¥ç‰©è½‰é‹é«”äº¤äº’ä½œç”¨ |

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šCYP3A4 ä»£è¬è—¥ç‰©ï¼Œè‘¡è„æŸšå¯èƒ½å½±éŸ¿ä»£è¬
- å»ºè­°ï¼šåŒ–ç™‚æœŸé–“é¿å…è‘¡è„æŸš



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Gastrointestinal Diseases** ğŸŸ¡ Moderate
- Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or ...

**Neuromuscular Diseases** ğŸŸ¡ Moderate
- Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness whil...

**Respiratory Insufficiency** ğŸŸ¢ Minor
- Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to sever...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¢ Minor
- Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in pati...

**Infections** ğŸŸ¢ Minor
- Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or ...

*å¦æœ‰ 1 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Vinorelbine åœ¨å¤šé …å…’ç«¥è…«ç˜¤è‡¨åºŠè©¦é©—ä¸­é¡¯ç¤ºå° Ewing è‚‰ç˜¤å…·æœ‰æ½›åœ¨ç™‚æ•ˆï¼Œä¸”ä½œç”¨æ©Ÿè½‰ï¼ˆå¾®ç®¡æŠ‘åˆ¶ï¼‰å°é«˜å¢æ®–æ€§è…«ç˜¤å…·æœ‰åˆç†çš„ç”Ÿç‰©å­¸åŸºç¤ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ”¶é›†å°ˆé–€é‡å° Ewing è‚‰ç˜¤çš„ç™‚æ•ˆæ•¸æ“š
- ç¢ºå®šé©ç•¶çš„å…’ç§‘åŠ‘é‡å’Œçµ¦è—¥æ–¹æ¡ˆ
- èˆ‡ç¾æœ‰ Ewing è‚‰ç˜¤æ¨™æº–æ²»ç™‚æ–¹æ¡ˆçš„æ¯”è¼ƒè©•ä¼°
- éª¨é«“æŠ‘åˆ¶å’Œç¥ç¶“æ¯’æ€§çš„å¯†åˆ‡ç›£æ¸¬è¨ˆç•«


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Propantheline]({{ "/drugs/propantheline/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dorzolamide]({{ "/drugs/dorzolamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Prednisolone]({{ "/drugs/prednisolone/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Vinorelbineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/vinorelbine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_vinorelbine,
  title = {Vinorelbineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/vinorelbine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
